<DOC>
	<DOCNO>NCT00352521</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also block blood flow tumor . Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together irinotecan may kill tumor cell . Diagnostic procedure , MRI , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This phase II trial study well give bevacizumab together irinotecan work treat patient recurrent malignant glioma well MRI predict response treatment .</brief_summary>
	<brief_title>Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) With Bevacizumab Irinotecan Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Examine effect bevacizumab irinotecan vascular permeability blood flow patient recurrent malignant glioma . Secondary - Determine reproducibility dynamic contrast-enhanced ( DCE-MRI ) malignant glioma . - Determine predictive value DCE-MRI patient recurrent malignant glioma treat bevacizumab irinotecan . - Describe activity combination bevacizumab irinotecan measure response rate progression-free survival . - Describe toxicity associate administration bevacizumab irinotecan . OUTLINE : Patients receive bevacizumab IV day 1 , 15 , 29 irinotecan IV day 2 , 15 , 29 first 6-week cycle . After first cycle , irinotecan bevacizumab give day 1 , 15 29 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Patients also undergo dynamic contrast-enhanced MRI 4 time .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follow malignant glioma : Glioblastoma multiforme Anaplastic astrocytoma Grade 3 great WHO astrocytic , oligodendroglial , mixed glial tumor initially diagnose histologic examination tumor specimen obtain biopsy resection Recurrent disease No 3 prior recurrence Measurable recurrent residual primary CNS neoplasm contrastenhanced MRI CT scan No evidence CNS hemorrhage baseline MRI CT scan PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Hematocrit &gt; 29 % Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 125,000/mm³ Creatinine &lt; 1.5 mg/dL SGOT &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception No active infection No significant traumatic injury within past 28 day PRIOR CONCURRENT THERAPY : At least 6 week since prior surgical resection More 28 day since prior major surgical procedure open biopsy More 7 day since prior minor surgical procedure , fineneedle aspiration , core biopsy At least 6 week since prior chemotherapy* At least 4 week since prior radiotherapy* No concurrent immunosuppressive agent No concurrent therapeutic anticoagulation Concurrent corticosteroid allow dose stable 1 week prior study entry NOTE : * Unless unequivocal evidence progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>